Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience (NASDAQ: TWST), a synthetic DNA manufacturer, announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO and co-founder Emily M. Leproust, Ph.D., along with CFO Adam Laponis, will engage in a fireside chat on December 3, 2024, at 10:00 a.m. Eastern Time in Coral Gables, Florida. The event will be accessible via live webcast through the company's investor relations website, with a replay available for 30 days after the presentation.
Twist Bioscience (NASDAQ: TWST) has announced new equity awards as employment inducements under Nasdaq Rule 5635(c)(4). The company granted 110,300 restricted stock units (RSUs) to 43 new employees and up to 37,500 performance stock units (PSUs) to VP Colby Souders. The RSUs vest over 48 months, with 25% vesting after one year and 1/16 vesting quarterly thereafter. The PSUs vest based on performance metrics for FY2024-2026, with potential earnings of 80%-150% of target, subject to continued employment.
Twist Bioscience (NASDAQ: TWST) has launched the FlexPrep™ Ultra-High Throughput Library Preparation Kit, featuring proprietary Normalization by Ligation™ technology. The kit enables processing of thousands of samples at low cost, eliminating the need for upfront sample quantitation and allowing early sample pooling. Researchers can run up to 1,152 samples in a single 96-well plate, reducing consumables by 12x and pipette tips usage from 17,000 to under 4,000. The company is collaborating with Gencove to provide genomic analysis software, offering an end-to-end workflow solution for agricultural and population genomics applications.
Twist Bioscience (NASDAQ: TWST) has announced it will release its fiscal 2024 fourth quarter and full year financial results on November 18, 2024, before market opening. The company will host a conference call and live audio webcast for analysts and investors at 8:00 AM Eastern Time. Participants interested in joining via telephone must register through the company's Investor Relations website. A webcast replay will be available for two weeks following the call.
Twist Bioscience (NASDAQ: TWST) has entered into a royalty purchase agreement with XOMA Royalty (NASDAQ: XOMA). Under the agreement, XOMA Royalty will provide Twist with an upfront payment of $15 million in exchange for the right to receive half of the future potential milestone and royalty payments from Twist's existing antibody discovery and biopharma services collaborations.
Twist will retain all upfront, service, and other revenue from these collaborations, as well as full rights to future biopharma collaborations with milestone and royalty terms. The agreement does not apply to synbio, NGS, or data storage revenue. This deal aims to provide Twist with immediate capital to support continued innovation and profitable growth across the company.
Twist Bioscience (NASDAQ: TWST) has appointed Mike Fero, Ph.D., as Chief Information Officer. Dr. Fero brings over 30 years of experience in startups, commercial software development, biology and physics research, and deep-tech businesses. His background includes building scalable enterprise software platforms and understanding systems biology and artificial intelligence. Dr. Fero was previously a Twist customer, giving him unique insights into the company's mission.
Before joining Twist, Dr. Fero co-founded and served as CEO of TeselaGen Biotechnology for a decade, developing an enterprise software platform for DNA design and management. He has also held positions at Stanford University, Neomorphic, HyperParallel, and MIT. Dr. Fero holds a Ph.D. in Physics and a B.A. in Math and Physics from UC Irvine.
Twist Bioscience (NASDAQ: TWST) has achieved LEED certification for its Wilsonville, OR facility, demonstrating its commitment to sustainability in operations and maintenance. The certification, awarded by the U.S. Green Building Council, recognizes the facility's adherence to LEED v4.1 Operations + Maintenance standards.
CEO Emily M. Leproust emphasized that this achievement aligns with Twist's mission to improve health and sustainability. The company previously quantified the carbon footprint of gene production using their platform, showing significant environmental benefits compared to traditional methods. This LEED certification further solidifies Twist's commitment to providing customers with DNA produced in a sustainable facility using fewer chemical reagents.
Twist Bioscience (NASDAQ: TWST) has released its 2024 corporate responsibility report, highlighting its commitment to sustainability, social responsibility, and ethics. The company's silicon-based DNA manufacturing platform offers a more sustainable alternative to legacy methods, using 99.8% less reagents than 96-well plate approaches.
Key points:
- Twist's oligo manufacturing process for NGS target enrichment panels emits significantly less CO2 compared to industry standards
- The company disclosed its Scope 1 and Scope 2 emissions for the first time
- Twist prioritizes biosecurity, cybersecurity, and data protection
- The company fosters a diverse workforce, with 56% of U.S. employees identifying as individuals of color
- Twist invested over $220,000 in employee learning and development in fiscal 2023
Twist Bioscience (NASDAQ: TWST), a leading synthetic DNA provider, has announced its participation in the Baird Global Healthcare Conference 2024. Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present on Tuesday, September 10 at 2:35 p.m. Eastern Time in New York City.
The presentation will be webcast live and accessible through the company's investor relations website. A replay will be available for 30 days following the event. This conference appearance provides an opportunity for Twist Bioscience to showcase its silicon-based DNA synthesis platform and engage with healthcare industry professionals and investors.
Twist Bioscience (NASDAQ: TWST) has expanded its DNA synthesis offering with the launch of Gene Fragments ranging from 1.8kb to 5.0kb in length. This industry-leading product is available through Twist's ecommerce platform, offering the same speed, quality, and affordability as shorter fragments. Key features include:
- Turnaround time starting at two business days
- Low error rate of 1:7,500 base pairs
- Customizable with no order limit
- Universally compatible with various downstream cloning methods
The expanded offering aims to serve researchers at all stages, from Makers to Buyers, and is particularly beneficial for RNA therapeutic screening applications. Twist's CEO, Emily M. Leproust, Ph.D., emphasized the company's goal to push the boundaries of DNA synthesis and meet diverse customer needs.
